A randomized trial of edivoxetine in pediatric patients with attention-deficit/hyperactivity disorder

Abstract

Objective: The purpose of this study was to assess the efficacy and safety of edivoxetine (LY2216684), a selective norepinephrine reuptake inhibitor, in pediatric patients with attention-deficit/hyperactivity disorder (ADHD).

Method: A fixed-dose, randomized, double-blind, 8 week study was conducted in patients 6-17 years of age, who were randomized by two strata: 1) Patients with prior stimulant use randomized to placebo, edivoxetine 0.1 mg/kg/day, 0.2 mg/kg/day, or 0.3 mg/kg/day arms in a 1:1:1:1 ratio; 2) Stimulant-naïve patients randomized to placebo, edivoxetine 0.1mg/kg/day, 0.2 mg/kg/day, 0.3 mg/kg/day, or osmotic-release oral system methylphenidate (OROS MPH) (18-54 mg/day based on body weight) arms in a 1:1:1:1:1 ratio. The primary efficacy measure was baseline-to-week 8 change of ADHD Rating Scale (ADHD-RS) total score for edivoxetine 0.2 mg/kg/day and 0.3 mg/kg/day.

Results: A total of 340 patients were randomized to placebo (n=78); edivoxetine 0.1 mg/kg/day (n=76), 0.2 mg/kg/day (n=75), or 0.3 mg/kg/day (n=75); or OROS MPH (n=36). In the stimulant-naïve stratum, the positive control, OROS MPH, was significantly superior to placebo in mean ADHD-RS total score change at end-point (-19.46, p=0.015). The edivoxetine 0.2 mg/kg/day and 0.3 mg/kg/day arms had statistically significantly greater improvement than the placebo arm in mean ADHD-RS total score change at end-point (placebo -10.35; edivoxetine 0.2 mg/kg/day -16.09, p<0.010; edivoxetine 0.3 mg/kg/day -16.39, p<0.010) and Clinical Global Impressions-Improvement score (placebo 3.05; edivoxetine 0.1 mg/kg/day 3.01, p=0.860; edivoxetine 0.2 mg/kg/day 2.54, p=0.013; edivoxetine 0.3 mg/kg/day 2.53, p=0.013). In the overall efficacy-analyses data set (n=270), the effect size estimates for edivoxetine doses 0.1 mg/kg/day, 0.2 mg/kg/day and 0.3 mg/kg/day at the week 8 time point were 0.17, 0.51, and 0.54, respectively (for the stimulant-naïve stratum, the effect size estimate for OROS MPH was 0.69). Compared with placebo, edivoxetine treatment was associated with statistically significant increases in blood pressure and pulse (p<0.050), and a smaller increase or slight decrease in weight.

Conclusions: Edivoxetine at doses of 0.2 mg/kg/day and 0.3 mg/kg/day demonstrated efficacy in ADHD treatment, despite the presence of a sizeable placebo response. No unexpected adverse events were identified. Clinical Trial Registry identifier: NCT00922636.

Figures

FIG. 1.

Study design. aIncludes patients with prior stimulant treatment and patients with no prior stimulant treatment. bTitration to target dose was based on patient's weight (methylphenidate dose=18 mg [18.0–23.9 kg], 36 mg [24.0–41.9 kg], 54 mg [42.0–≤75 kg]). cIncludes only patients with no prior stimulant treatment. dPatients unable to tolerate the assigned dose during Study Period II were discontinued from the study and returned for a safety follow-up visit at visit 301 (end-point for Study Period III). ePatients were first stratified based on previous stimulant treatment history, then randomized; stimulant-naïve patients were randomized at a ratio of 1:1:1:1:1 to placebo, extended-release methylphenidate, or one of three fixed-dose arms of edivoxetine (targeted doses of 0.1, 0.2, or 0.3 mg/kg); stimulant-prior patients were randomized at a ratio of 1:1:1:1 to placebo or one of three fixed-dose arms of edivoxetine. wk=week.

FIG. 2.

Patient disposition in the efficacy analyses data set (potentially unblinded patients excluded). 0.1=0.1 mg/kg/day; 0.2=0.2 mg/kg/day; 0.3=0.3 mg/kg/day; OROS MPH=osmotic-release oral system methylphenidate; n/N=number of patients.

FIG. 3.

Primary efficacy measure in the efficacy analyses data set: Baseline-to-endpoint change in ADHD-RS-IV-Parent:Inv total score according to per-protocol analysis of patients with previous stimulant exposure (A: left panel) and stimulant-naive patients (B: right panel). *p<0.05 edivoxetine vs. placebo; **p<0.05 methylphenidate (MPH) vs. placebo. 0.1=0.1 mg/kg/day; 0.2=0.2 mg/kg/day; 0.3=0.3 mg/kg/day; ADHDRS-IV-Parent:Inv=Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator Administered and Scored; LS=least squares; MMRM=mixed model repeated measures; OROS MPH=osmotic-release oral system methylphenidate.